{"ticker": {"uuid": "9c377fed-778b-43d2-a52c-2563b3e84e8b", "symbol": "NWRN", "name": "Newron Pharmaceuticals S.p.A.", "exchange": "EBS", "country": "CH", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Newron Pharmaceuticals to Make Changes to Phase 3 Trial of Schizophrenia Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxPWVA4Z1hWYjdVTnFEZF84YkdnN0RXTGFKY0FJVVYtZGtKTmhNNlpSd3lPd244R0dIUmNVaTNkbDg0RmQ3dE1wMHM0c2huY0JVRFhRMWkwZmM1emJwdlhrTEJaWWRtZnRxMFlIVGY5Mk9wV3NuWVBhYmdiWFJnVzhBb0s3TXlFbHZRZEtUTXBGYXliQ25GVWZWTUNGZE5FaFY3WVFkWHl2MVVyQkgwa1FDcnNvSzZCWnZlUVdPcUx5R2pCU3JncFlfX2dWLTVNaUNz?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-03T04:11:13+00:00", "published_display": "03 Jul 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Newron Pharmaceuticals S.p.A. (VTX:NWRN) Analysts Just Slashed This Year's Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQQXpzNTgydlRQU0lMVDhIcG5XaHF0amJVRUxGdC15RXBQX0xJZlNEV2hLbUZwX25FSjlMVktKbXhobEl6NGJXOFA5RUlfbVhUWERHRHhrajBZcGRRQUJ0al8zZVlOeDlyZ05WU2pDZHRrS1IyYk5nNFR6a0pCX0lqNmZ1RzE3WjVlVDB5b1V0R2x3dWFQcUZBcUhiR3JteVU?oc=5", "source_name": "Market source", "published_at": "2026-03-28T07:00:00+00:00", "published_display": "28 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQRVVUOWQ4S3FiZUFCMkwwWld2UE1ldWJ2ZTJEdlNVS05Wd2hRbTMtZVh1Sk1Ma2s3cE1wS0RGMDFLTzFBb2lKdEs1TzE0UjVGdExYUUQtM3FGM0lkUE10T29xNi1zbUhTQ0NzNF9jSEVkSW5RUkFub3ctX2EtZUxLWHBQSXZLR1lydkZFUWtEY3FlZGNoZmNmMnBYWEpUcEluQklabGpWeG1RQjFzSERhOWhIVTk3T1RFM2NjeGp1UFhMRWtBSWVkbC1aMA?oc=5", "source_name": "Business Wire", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What You Need To Know About The Newron Pharmaceuticals S.p.A. (VTX:NWRN) Analyst Downgrade Today", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-16T08:00:00+00:00", "published_display": "16 Dec 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Newron Pharmaceuticals S.p.A.: Target Price Consensus and Analysts Recommendations | NWRN | IT0004147952", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPZkNENVNFekJFOGpRTWtWakRtNlBMaldaRG1zUWFYakFDN3lSSld1WlQ4M2RHUEZSS09aek1oSDJJMlQ4T0puNjdMOVhXY1Y4UFFzeUtLS0lTbGdrOFZfWkh1LWtxQ0VxNURCRU1sQVRSRExMTE1HRVlBSy1rQndUb3VMTk44X0ItZ21ZajRkcw?oc=5", "source_name": "marketscreener.com", "published_at": "2023-06-25T06:00:00+00:00", "published_display": "25 Jun 2023 06:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Newron Pharmaceuticals S.p.a Stock Price Forecast. Should You Buy NWRN.SW?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTEFVX3lxTE8ySElnRDlzVVFPUWUzUEk2RUIyMmJQWWQwTjlvaUNZc3BrOTNDS29ZMzJhcXd4TFU1VjU5RC1Dd0xQWUNlVVUtcW8yMEQ?oc=5", "source_name": "StockInvest.us", "published_at": "2020-12-14T20:04:07+00:00", "published_display": "14 Dec 2020 20:04", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Newron Pharmaceuticals to Make Changes to Phase 3 Trial of Schizophrenia Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxPWVA4Z1hWYjdVTnFEZF84YkdnN0RXTGFKY0FJVVYtZGtKTmhNNlpSd3lPd244R0dIUmNVaTNkbDg0RmQ3dE1wMHM0c2huY0JVRFhRMWkwZmM1emJwdlhrTEJaWWRtZnRxMFlIVGY5Mk9wV3NuWVBhYmdiWFJnVzhBb0s3TXlFbHZRZEtUTXBGYXliQ25GVWZWTUNGZE5FaFY3WVFkWHl2MVVyQkgwa1FDcnNvSzZCWnZlUVdPcUx5R2pCU3JncFlfX2dWLTVNaUNz?oc=5", "source_name": "marketscreener.com", "published_at": "2026-07-03T04:11:13+00:00", "published_display": "03 Jul 2026 04:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Newron Pharmaceuticals S.p.A. (VTX:NWRN) Analysts Just Slashed This Year's Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxQQXpzNTgydlRQU0lMVDhIcG5XaHF0amJVRUxGdC15RXBQX0xJZlNEV2hLbUZwX25FSjlMVktKbXhobEl6NGJXOFA5RUlfbVhUWERHRHhrajBZcGRRQUJ0al8zZVlOeDlyZ05WU2pDZHRrS1IyYk5nNFR6a0pCX0lqNmZ1RzE3WjVlVDB5b1V0R2x3dWFQcUZBcUhiR3JteVU?oc=5", "source_name": "Market source", "published_at": "2026-03-28T07:00:00+00:00", "published_display": "28 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Newron Secures Up to EUR 38 Million to Advance Phase III Evenamide Program", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQRVVUOWQ4S3FiZUFCMkwwWld2UE1ldWJ2ZTJEdlNVS05Wd2hRbTMtZVh1Sk1Ma2s3cE1wS0RGMDFLTzFBb2lKdEs1TzE0UjVGdExYUUQtM3FGM0lkUE10T29xNi1zbUhTQ0NzNF9jSEVkSW5RUkFub3ctX2EtZUxLWHBQSXZLR1lydkZFUWtEY3FlZGNoZmNmMnBYWEpUcEluQklabGpWeG1RQjFzSERhOWhIVTk3T1RFM2NjeGp1UFhMRWtBSWVkbC1aMA?oc=5", "source_name": "Business Wire", "published_at": "2026-02-16T08:00:00+00:00", "published_display": "16 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "What You Need To Know About The Newron Pharmaceuticals S.p.A. (VTX:NWRN) Analyst Downgrade Today", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-16T08:00:00+00:00", "published_display": "16 Dec 2025 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Newron Pharmaceuticals S.p.A.: Target Price Consensus and Analysts Recommendations | NWRN | IT0004147952", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxPZkNENVNFekJFOGpRTWtWakRtNlBMaldaRG1zUWFYakFDN3lSSld1WlQ4M2RHUEZSS09aek1oSDJJMlQ4T0puNjdMOVhXY1Y4UFFzeUtLS0lTbGdrOFZfWkh1LWtxQ0VxNURCRU1sQVRSRExMTE1HRVlBSy1rQndUb3VMTk44X0ItZ21ZajRkcw?oc=5", "source_name": "marketscreener.com", "published_at": "2023-06-25T06:00:00+00:00", "published_display": "25 Jun 2023 06:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Newron Pharmaceuticals S.p.a Stock Price Forecast. Should You Buy NWRN.SW?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiTEFVX3lxTE8ySElnRDlzVVFPUWUzUEk2RUIyMmJQWWQwTjlvaUNZc3BrOTNDS29ZMzJhcXd4TFU1VjU5RC1Dd0xQWUNlVVUtcW8yMEQ?oc=5", "source_name": "StockInvest.us", "published_at": "2020-12-14T20:04:07+00:00", "published_display": "14 Dec 2020 20:04", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 65, "total_relevant": 6, "sentiment_summary": {"positive": 1, "negative": 1, "neutral": 4, "score": 50, "total": 6, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 68, "events": [{"event": "general", "label": "Market update", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 1, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 11.8, "latest_week": "2026-07-10", "one_week_move": -3.3, "four_week_move": -2.2, "twelve_week_move": -28.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.690038, "market_dynamics_buy_signal": false, "relative_strength": -27.455611, "fair_value_gap": 18.4, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 46.2016, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.3% over one week, -2.2% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 54, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "marketscreener.com", "count": 2}, {"label": "Market source", "count": 1}, {"label": "Business Wire", "count": 1}, {"label": "simplywall.st", "count": 1}, {"label": "StockInvest.us", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 6}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 3}, {"label": "Analyst action", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "50/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "68/100 classification confidence."}, {"label": "Company focus", "value": "6", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-3.3% over one week, -2.2% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Newron Pharmaceuticals to Make Changes to Phase 3 Trial of Schizophrenia Treatment"}], "updated_at": "2026-07-17T07:06:00.634262+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}